Adverse event reporting
ADVERSE EVENT
Safety was assessed for the 61 participants. The number of days of seal use during the intervention period was 5.6 ± 1.2 and 5.4 ± 1.3 days per week in the aroma- and placebo-seal use groups, respectively, and all 61 participants completed the two weeks of the intervention period. One adverse event (3.2%) each was reported in the aroma- and placebo-seal use groups (